A5012450137- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Radiopharmaceutical Chemistry and Applications
- Reconstructive Surgery and Microvascular Techniques
- Cancer-related cognitive impairment studies
- Breast Implant and Reconstruction
- Peptidase Inhibition and Analysis
- Pediatric Hepatobiliary Diseases and Treatments
- Lung Cancer Diagnosis and Treatment
- Organ and Tissue Transplantation Research
University of Rochester
2018-2025
University of Rochester Medical Center
2020-2024
KIST Medical College
2019-2022
Nepal Medical College Teaching Hospital
2021
Rochester General Hospital
2021
Bassett Medical Center
2021
Roswell Park Comprehensive Cancer Center
2017-2021
University at Buffalo, State University of New York
2015
Maimonides Medical Center
2013-2014
Kathmandu Medical College Teaching Hospital
1970-2008
Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in
Abstract Brain metastases (BrM) arising from solid tumors is an ever increasing and often devastating clinical challenge impacting hundreds of thousands patients annually worldwide. As systemic anticancer therapies, thus survival, improve, risk for central nervous system (CNS) recurrence has increased. Historically, with BrM were excluded trials; however, there been a shift towards inclusion over the past decade. To most effectively design next generation trials BrM, multidisciplinary team...
Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in management hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), optimal sequence therapy is unclear. There are no clinical data on efficacy HR+ HER2-MBC after progresses inhibitors.The objective this study to find they progress a palbociclib.This retrospective, 2-institute review from Jan 2015 March 2018 treated with progression palbociclib. Primary end point was median...
Abstract Background: Imlunestrant is a novel, orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties that result in sustained inhibition of (ER)-dependent gene transcription and cell growth. Preclinically, imlunestrant has favorable efficacy pharmacokinetic (PK) properties, including antitumor activity ESR1-mutant models, along enhanced when combined abemaciclib. In dose escalation (Phase 1a) expansion 1b) the EMBER study, monotherapy was well...
Outcome data on hormone receptor positive (HR
Abstract Background: Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader, designed to deliver continuous ER target inhibition, including in ESR1-mutant breast cancer. In the first-in-human dose escalation/expansion (Phase 1a/1b) study of EMBER trial (NCT04188548), imlunestrant showed favorable safety, pharmacokinetics, and clinical benefit pre-treated patients with ER+, HER2- aBC when administered as monotherapy (Jhaveri, ASCO 2022) or abemaciclib ± aromatase...
Bortezomib, a proteasome inhibitor, is an established therapy against multiple myeloma. Bortezomib-induced lung injury, although not appreciated during the introductory time of medication, has now been highlighted in case reports. The objective this study to report bortezomib-induced review current literature, and perform exploratory analysis.
Abstract Objectives We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)–expressing nonexpressing microinvasive breast carcinomas (MiBC) to explore significance HER2 in MiBC. Methods Clinicopathologic follow-up information cases with final diagnosis MiBC known status between 2007 2019 were analyzed. Results Nineteen (41.3%) HER2-positive (HER2+) 27 (58.7%) HER2-negative (HER2−) MiBCs identified. positivity was likely...
Abstract A 72-year-old female presented to the emergency department with sudden onset of imbalance and cognitive decline. Two years ago, she was diagnosed stage III estrogen receptor (ER) positive, progesterone (PR) negative human epidermal growth factor 2 (HER2) (immunohistochemistry score: 0) invasive breast cancer. She subsequently underwent lumpectomy, adjuvant radiation chemotherapy. had been taking letrozole at time presentation. Magnetic resonance imaging (MRI) brain showed...
Abstract BACKGROUND: Immune checkpoint inhibitors in combination with chemotherapy have demonstrated an improvement of pathologic complete response (pCR) patients HR-HER2- and MammaPrint (MP) High Risk, HR+HER2- tumors the I-SPY2 TRIAL. However, not all benefit from immune blockade these new agents come additional financial burden significant long-lasting side effects such as adrenal insufficiency. Thus, it is imperative to better understand who benefits. Response Predictive Subtypes (RPS)...
1054 Background: Resistance mechanisms to CDK 4/6 inhibition are not well defined. Outcome data on hormone receptor positive (HR+) metastatic breast cancer patients (MBCP) treated with palbociclib (PA) after treatment everolimus (EV) lacking. The PALOMA 3 trial (P3) showing benefit of PA plus fulvestrant (FU) compared FU in HR+ MBCP progression endocrine therapy excluded women previously EV. aim our study was investigate the outcomes prior EV based therapy. Methods: This is a retrospective,...
Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline treatment option for metastatic hormone receptor–positive breast cancer. Approximately, 25% to 30% of women may have resistance endocrine therapy, especially in setting certain genomic mutations tumor. This prompts need identify those patients who benefit from chemotherapy over therapy. Here, we present a case patient presented de novo cancer visceral involvement (including bone marrow) as well multiple...
Abstract Background: Breast cancer brain metastasis (bcbm) is associated with limited survival. There a paucity of clinical trials and real-world data on the survival disease interval [primary breast (pbc) to metastatic (mbc) or bcbm] bcbm patients. We performed retrospective study comparing overall (OS) intervals (INT) between date pbc surgery, diagnoses mbc, among 3 subtypes bc in patients bcbm. Methods: The informatics team generated preliminary list history who were treated at Wilmot...
Abstract The objective of the study is to assess impact systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach categorize SD among breast cancer (BC) patients. This single institution retrospective included BCBM patients who have received stereotactic radiosurgery (SRS) brain. Separate endpoints [CNS failure-free (cFFS), (OS)] were analyzed from each Landmark (LM): LM1 (3-months), LM2 (6-months). Patients categorized into early...
We report the efficacy of trastuzumab deruxtecan (T-DXd) in treating human epidermal growth factor receptor 2 (HER2) low, type ID leptomeningeal breast cancer (LMD) (with positive cerebrospinal fluid [CSF] cytology and hydrocephalus as only abnormal imaging finding) diagnostic monitoring utilization a novel microfluidic platform called CNSide™. Breast LMD is associated with poor prognosis, effective treatments are lacking. Our case highlights two crucial aspects related to treatment LMD....
Laparoscopic cholecystectomy is a gold standard treatment for gall stone diseases. Early surgical intervention in acute calculus cholecystitis feasible and duration of onset symptoms does not influence the conversion rate.To compare safety feasibility between urgent delayed laparoscopic patients with cholecystitis.This comparative study conducted Department Surgery, Kathmandu Medical College, during period January 2006 to 2008. Alltogether, 436 were analysed out which 55 selected as included...